Alfred Furth

Learn More
The purpose of this study was to establish an accurate and accessible immunohistochemical (IHC) method for detecting vIII Egf receptor and to assess the prognostic significance of the method as applied to the detection of vIII in malignant astrocytomas. The accuracy of the method was determined by comparing vIII immunoreactivity in formalin-fixed and(More)
PURPOSE This phase I study was conducted to determine the toxicities, pharmacokinetics, and pharmacodynamics of BMS-214662, a farnesyl transferase inhibitor, in combination with paclitaxel and carboplatin, in patients with advanced solid tumors. EXPERIMENTAL DESIGN Patients with solid tumors received one of six escalating dose levels of BMS-214662 infused(More)
Although the three-outcome phase II clinical trial design (Sargent et al., 2001) has seen increasing use, confidence interval methodology for the binary endpoint had not been explicitly defined. Typical phase II clinical trial designs with binomial endpoints use a sequential binomial confidence interval (SBCI) algorithm (Duffy and Santner, 1987). We(More)
  • 1